



**General Medicine:
NAUSEA AND VOMITING
Practice Guideline**

Patient Care Goals
1. Decrease discomfort secondary to nausea and vomiting.

Patient Presentation:
Inclusion Criteria
1. Patient experiencing nausea and/or vomiting.

Exclusion Criteria
1. History of Congenital/Acquired Prolonged QTc Syndrome.

Patient Management:
Apply Universal Care Guideline to assess for underlying conditions causing nausea and/or vomiting. Nausea and/or vomiting are symptoms-not a diagnosis.

Ondansetron
ODT: 15-30kg: 4 mg
>30kg: 8 mg
IV/IO: 0.1 mg/kg MAX 4 mg

Diphenhydramine
IM/IV/IO: 1 mg/kg MAX 25 mg

Patient Safety Considerations:
1. At larger doses than our Practice Guidelines allow, ondansetron may pose risk in patients with prolonged QTc >470 ms. An ECG solely to determine QTc is unnecessary prior to administering ondansetron within Practice Guideline ranges but may be used as another data point or if the dosing is exceeded in conjunction with OLMC.
2. There is inconclusive/inadequate data on safety of ondansetron in first trimester pregnancy; dose range within our Practice Guideline range is reasonable.

Quality Improvement:
Per Narrative Documentation for PCR Operational Policy

Performance Measures
1. Response to medication documentation.

